Cargando…
1575 A 28-day high-dose safety and pharmacokinetics study of raltegravir in healthy subjects
Autores principales: | Krishna, Rajesh, Rizk, Matthew, Schulz, Valerie, Bruggencate-Broeders, Jolanda, Liu, Ran, Larson, Patrick, Abou-Farha, Khalid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781577/ http://dx.doi.org/10.1093/ofid/ofu052.1121 |
Ejemplares similares
-
936 Tolerability, Adherence and Completion of New Occupational HIV Post-Exposure Prophylaxis Regimens (Tenofovir + Emtricitabine and Raltegravir)
por: Bock, Izona, et al.
Publicado: (2014) -
1617 Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents – a 24 Week Study
por: Teppler, Hedy, et al.
Publicado: (2014) -
1529 Raltegravir Plus Tenofovir DF and Emtricitabine for Non-occupational Postexposure Prophylaxis (nPEP): African-Americans are at Higher Risk of Non-Completion of nPEP
por: Vigil, Karen J., et al.
Publicado: (2014) -
297 Trends in Staphylococcus aureus (SA) Isolation in 28 US Hospitals, 2009-2013
por: Diekema, Daniel J., et al.
Publicado: (2014) -
394 Influence of febrile neutropenia on the pharmacokinetics and dosage requirements of vancomycin
por: Shiotsuka, Shouichi, et al.
Publicado: (2014)